Wuhan Hiteck Biological Pharma Co.,Ltd reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 277.45 million compared to CNY 384.2 million a year ago. Revenue was CNY 286.45 million compared to CNY 387.23 million a year ago.

Net loss was CNY 11.13 million compared to net income of CNY 18.87 million a year ago. Basic loss per share from continuing operations was CNY 0.09 compared to basic earnings per share from continuing operations of CNY 0.15 a year ago. Diluted loss per share from continuing operations was CNY 0.09 compared to diluted earnings per share from continuing operations of CNY 0.15 a year ago.